Mitsuyoshi Yoshimoto

Effects of radiation on the stability of monoclonal antibodies and implications for radionuclide labeled monoclonal antibodies in theranostics

Teppei Shimizu, Shoko Ohashi, Mitsuyoshi Yoshimoto, Eiichi Yamamoto et autres

jp (code pays fourni par la source)

First-in-human phase I study of hypoxia-targeting 64Cu-ATSM radioligand therapy in patients with malignant brain tumors (STAR-64)

H. Kurihara, Y. Narita, Kimiteru Ito, H. Sato et autres

jp, us (code pays fourni par la source)

Enhanced Radionuclide Therapy via the Conjugation of Pentadecanoic Acids With 225 Ac ‐ and 177 Lu ‐Labeled RGD Peptides

Mitsuyoshi Yoshimoto, Shun‐ichi Wada, Yukie Yoshii, Sayaka Hanadate et autres

jp, cz (code pays fourni par la source)

First-in-human phase 0 safety, imaging, pharmacokinetics, and dosimetry study of 64 Cu-PD-32766, a carbonic anhydrase IX (CAIX)-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC).

Toshihiro Horii, Mitsuyoshi Yoshimoto, Akinori Kobayashi, Chihiro Kondo et autres

jp (code pays fourni par la source)

Long-Term Therapeutic Effects of 225Ac-DOTA-E[c(RGDfK)]2 Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma

Mitsuyoshi Yoshimoto, Kohshin Washiyama, Kazunobu Ohnuki, Ayano Doi et autres

jp, us (code pays fourni par la source)

αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine

Mitsuyoshi Yoshimoto, Takuya Hayakawa, Masayuki Yamaguchi, Sadaaki Kimura et autres

Phase I clinical trial of 64Cu-ATSM for malignant brain tumors.

Hiroaki Kurihara, Yoshitaka Narita, Kimiteru Ito, Hidemitsu Sato et autres

jp (code pays fourni par la source)

The safe handling of 211At compounds

Kazunobu Ohnuki, Yasumasa Takenaka, Mitsuyoshi Yoshimoto, Hirofumi Fujii

jp (code pays fourni par la source)

Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide

Kazunobu Ohnuki, Mitsuyoshi Yoshimoto, Hiromitsu Haba, Shino Manabe et autres

jp (code pays fourni par la source)

In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized 64Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study

Fukiko Hihara, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, Takashi Masuko et autres

jp (code pays fourni par la source)

Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy

Mitsuyoshi Yoshimoto, Yukie Yoshii, Hiroki Matsumoto, Mitsuhiro Shinada et autres

jp (code pays fourni par la source)

Aminopolycarboxylate Chelators Are Effective for Whole-body Clearance of Free 225ac: A Method to Reduce Unexpected Radiation Exposure During Targeted Alpha Therapy

Mitsuyoshi Yoshimoto, Yukie Yoshii, Hiroki Matsumoto, Mitsuhiro Shinada et autres

jp (code pays fourni par la source)